ACT-541468

DRUG12 trials

Sponsors

Idorsia Pharmaceuticals Ltd.

Conditions

Chronic Obstructive Pulmonary DiseaseHealthyHealthy Recreational Drug UsersHealthy SubjectsInsomnia DisorderObstructive Sleep ApneaRenal Insufficiency

Phase 1

Pharmacokinetic Interaction Between Diltiazem and ACT-541468 in Healthy Subjects

CompletedNCT02526888

Idorsia Pharmaceuticals Ltd.Healthy Subjects

Start: 2015-09-01End: 2015-11-01Updated: 2018-07-10

A Clinical Study to Investigate the Potential Interactions Between Food and ACT-541468 and Between ACT-541468 and Midazolam

CompletedNCT03017495

Idorsia Pharmaceuticals Ltd.Healthy Subjects

Start: 2017-01-01End: 2017-02-01Updated: 2018-07-10

A Study of ACT-541468 in Healthy Japanese and Caucasian Subjects

CompletedNCT03101189

Idorsia Pharmaceuticals Ltd.Healthy Subjects

Start: 2017-03-15End: 2017-04-26Updated: 2018-07-10

A Study in Healthy Male Subjects to Investigate Whether Administration of ACT-541468 Can Affect the Fate in the Body (Amount and Time of Presence in the Blood) of Rosuvastatin

CompletedNCT03339752

Idorsia Pharmaceuticals Ltd.Healthy Subjects

Start: 2017-10-30End: 2017-12-02Updated: 2017-12-11

A Study to Investigate the Drug-drug Interactions Between ACT-541468 and Ethanol in Healthy Subjects

CompletedNCT03609775

Idorsia Pharmaceuticals Ltd.Healthy

Start: 2018-08-28End: 2018-10-09Updated: 2018-10-15

A Study to Evaluate the Effects of ACT-541468 on Respiration in Patients With Moderate Chronic Obstructive Pulmonary Disease

CompletedNCT03646864

Idorsia Pharmaceuticals Ltd.Chronic Obstructive Pulmonary Disease

Start: 2018-11-15End: 2019-09-19Updated: 2019-09-23

Study to Evaluate the Abuse Potential of ACT-541468 in Healthy Recreational Drug Users

CompletedNCT03657355

Idorsia Pharmaceuticals Ltd.Healthy Recreational Drug Users

Start: 2018-09-07End: 2019-08-08Updated: 2019-09-19

A Study to Investigate the Effects of ACT-541468 on Nighttime Respiratory Function in Patients With Mild to Moderate Obstructive Sleep Apnea

CompletedNCT03765294

Idorsia Pharmaceuticals Ltd.Obstructive Sleep Apnea

Start: 2019-03-14End: 2019-11-05Updated: 2019-12-19

A Clinical Study to Investigate the Food Effect on the Pharmacokinetics of ACT-541468 in Healthy Male Subjects

CompletedNCT03799978

Idorsia Pharmaceuticals Ltd.Healthy

Start: 2019-03-09End: 2019-03-18Updated: 2019-04-12

A Clinical Study to Assess Next-day Driving Performance Following Administration of ACT-541468 in Middle-aged and Elderly Subjects

CompletedNCT03892902

Idorsia Pharmaceuticals Ltd.Healthy

Start: 2019-03-25End: 2019-10-10Updated: 2019-10-31

Study of the Way the Body Takes up, Distributes, and Gets Rid of ACT-541468 in Subjects With Abnormal Kidney Function Compared to Healthy Subjects

CompletedNCT04024332

Idorsia Pharmaceuticals Ltd.Healthy, Renal Insufficiency

Start: 2019-09-24End: 2020-08-14Updated: 2020-09-03

Phase 2

Efficacy and Safety of ACT-541468 in Elderly Subjects With Insomnia Disorder

CompletedNCT02841709

Idorsia Pharmaceuticals Ltd.Insomnia Disorder

Start: 2016-11-28End: 2017-06-29Updated: 2020-04-24

Related Papers

Assessment of the effect of the dual orexin receptor antagonist daridorexant on various indices of disease severity in patients with mild to moderate obstructive sleep apnea.

2022-02-128 citations

Abuse potential assessment of the new dual orexin receptor antagonist daridorexant in recreational sedative drug users as compared to suvorexant and zolpidem

SLEEP2021-09-0442 citations

Effect of the new dual orexin receptor antagonist daridorexant on nighttime respiratory function and sleep in patients with mild and moderate obstructive sleep apnea

SLEEP2020-12-1141 citations

Pharmacological Interactions between the Dual Orexin Receptor Antagonist Daridorexant and Ethanol in a Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Four-Way Crossover Phase I Study in Healthy Subjects.

2020-11-1813 citations

Daridorexant, a new dual orexin receptor antagonist, in elderly subjects with insomnia disorder.

2020-04-2766 citations